New Delhi: An expert committee at the apex drug regulator, Central Drugs Standards Control Organisation (CDSCO) has deferred its earlier call on Serum Institute of India Pvt Ltd’s vaccine trial. Instead, the panel asked the firm to change its protocol for the phase II and III clinical trials of the vaccine candidate of University of Oxford.
“After detailed deliberation the committee recommended for amendment to the protocol… Accordingly, the firm should submit revised protocol for evaluation of the committee,” the minutes of the subject expert committee (SEC) meeting was quoted by Mint.
The regulatory panel, as part of amendment protocol, has asked the firm to demarcate trials of phase II and III and distribute it across India.
The company has also been asked to specify Indian Council of Medical Research’s (ICMR’s) role in the trial. The Mint report said that an email sent to Serum Institute of India was unanswered.
Stay ahead with Odisha Bytes Breaking News - your ultimate source for the fastest, most…
New Delhi: After the record-breaking success of ‘Pushpa 2: The Rule’, Rashmika Mandanna has her…
Bhubaneswar: Twelve members of Village Water and Sanitation Committees (VWSC) from nine districts of Odisha…
Hyderabad: Bollywood actress Janhvi Kapoor, who is rumoured to be dating Shikhar Pahariya, had once…
Bhubaneswar: In a remarkable stride toward strengthening industrial ecosystem, the Odisha government on Wednesday approved…
Bengaluru: Playing away from home, Odisha FC turned the game on its head to snatch a…
This website uses cookies.
